Document is current
Any future updates will be listed below
-
Authors
Ding, Ke
Li, Yupeng
Zhou, Yang
Huang, Weixue
- License Information
-
More Information
Article History
Received: 5 September 2025
Accepted: 11 January 2026
First Online: 10 April 2026
Compliance and ethics
: The authors declare that they have no conflict of interest. K.D. received royalties from Ascentage Pharma and Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm) based on the licensing agreements for Olverembatinib and Limertinib, respectively.
